ArticleHealth science reports2025
Evaluation of SARS-CoV-2 Variants After the Declaration of End of COVID-19 Pandemic: BA.2.86 (Pirola) and EG.5 (Eris) Variants as Global Public Health Concerns.
Article in Health science reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and Aims: Coronavirus disease 2019 (COVID-19) caused by SARS-CoV-2 was first reported to the World Health Organization (WHO) on December 31, 2019. The WHO declared the COVID-19 pandemic on March 11, 2020, after considering its impact on global public health. Therefore, we aim to assess the existing SARS-CoV-2 variants to understand their pathogenicity and threat after the pandemic phase of COVID-19 so that the healthcare authorities can take prompt preventive measures. Methods: We conducted a comprehensive literature search to gather information from publicly available sources. We extracted the relevant data from Google Scholar, PubMed, and Scopus. Results: The virus infected over 770 million people and caused more than 6.9 million deaths worldwide. Since the inception of COVID-19, the world has developed several therapeutic drugs and vaccines. Healthcare authorities worldwide have administered more than 13 billion vaccine doses. On May 5, 2023, the WHO declared the end of the COVID-19 pandemic based on its global threat and impacts on human health. However, SARS-CoV-2 continues to mutate to create new variants that can threaten global public health anytime. We observed that BA.2.86 (Pirola) and EG.5 (Eris) variants as global public health concerns. Conclusion: Genomic evolution of SARS-CoV-2 variants is a global public health concern for immune escape, vaccination effectiveness, therapeutic and diagnostic strategies. Therefore, we recommend close surveillance of these variants to determine their potential to cause severe disease and countermeasures.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.